Drugs / Goserelin
Goserelin
also known as
goserelin acetate · Zoladex · ZDX · goserelin acetate (Zoladex) · Goserelin Depot · NSC-606864 · ZOLADEXTM
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | ZOLADEX | — | 1993-02-02 – 1998-07-27 | fda.gov ↗ |
| Approved | US (FDA) | ZOLADEX | — | 1989-12-29 | fda.gov ↗ |
Trials 157 · started per year
today
US approved 1989
2
1
2
1
2
1
1
9
7
1
3
7
5
8
7
9
7
1
3
7
2
4
7
6
6
7
4
7
1
2
5
7
4
11
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials · 1 met primary | ||||||
| Phase 0 | NCT07516704 | Apr 2026 → Dec 2027 expected | prostate cancer | Zhongda Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03511196 | Sep 2018 → Jun 2022 overdue | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | Met primary |
| Phase 0 | NCT04060043 | Feb → Dec 2017 | prostate cancer | CMX Research | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT07310420 | Oct 2026 → Mar 2027 expected | female breast carcinoma | TerSera Therapeutics LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04428684 | Oct 2018 → Apr 2020 | uterine disorder | Peptigroupe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02023463 | Apr 2014 → Jul 2017 overdue | prostate adenocarcinoma | Thomas Jefferson University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02911350 | May 2000 → Dec 2016 | prostate cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00669162 | Aug 2012 → Aug 2016 | prostate cancer | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00653757 | Mar 2002 → Dec 2006 | prostate cancer | Mayo Clinic | Completed | No outcome recorded |
| Phase 268 trials · 3 met primary · 3 missed | ||||||
| Phase 2 | NCT07801898 | Sep 2026 → Sep 2028 expected | invasive breast carcinoma | The Second Hospital of Anhui Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07610733 | Jun 2026 → Sep 2027 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07460752 | May 2026 → Dec 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT07287098 | May 2026 → Jan 2029 expected | breast neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07450599 | Apr 2026 → Jun 2028 expected | — | Bayer | Recruiting | No outcome recorded |
| Phase 2 | NCT07158021 | Jan 2026 → Jan 2028 expected | female breast carcinoma, invasive breast carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07313241 | Nov 2025 → Nov 2030 expected | prostate cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06953882 | Jul 2025 → Sep 2030 expected | Her2-receptor negative breast cancer | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT06772441 | Nov 2024 → Oct 2026 expected | prostate cancer | German Oncology Center, Cyprus | Recruiting | No outcome recorded |
| Phase 2 | NCT06225284 | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06385847 | May 2024 → May 2025 | prostate cancer | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 2 | NCT06387056 | Apr 2024 → Apr 2026 overdue | metastatic prostate carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05607004 | Feb 2023 → Nov 2026 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma | Atossa Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05694819 | Apr 2020 → Aug 2024 | salivary gland cancer | National Cancer Center Hospital East | Completed | No outcome recorded |
| Phase 2 | NCT03942653 | May 2019 → Jul 2026 overdue | salivary gland carcinoma | Manish Patel | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03860987 | Apr 2019 → May 2026 | prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04536467 | Mar 2019 → Dec 2020 | primary ovarian failure | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2 | NCT03839823 | Feb 2019 → Apr 2022 | breast cancer | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03628066 | Oct 2018 → Nov 2020 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 2 | NCT03361735 | Aug 2018 → Mar 2024 overdue | prostate adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03475758 | Mar 2018 → Mar 2020 | primary ovarian failure | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT03444025 | Mar 2018 → Mar 2021 | triple-negative breast carcinoma | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02972060 | Dec 2017 → Jan 2023 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03279250 | Oct 2017 → May 2021 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03272477 | Oct 2017 → Jul 2020 | breast cancer | Palleos Healthcare GmbH | Completed | Met primary |
| Phase 2 | NCT02476786 | Jan 2017 → Jan 2027 expected | breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT02624973 | Apr 2016 → Jun 2020 overdue | breast cancer | Haukeland University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02544191 | Dec 2015 → Dec 2017 | azoospermia | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT02430480 | Jun 2015 → Dec 2019 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02603679 | Feb 2015 → Jul 2021 overdue | estrogen-receptor positive breast cancer | Thomas Hatschek | Active not recruiting | Missed primary |
| Phase 2 | NCT01989780 | Jan 2014 → Jun 2018 | breast cancer | Japan Breast Cancer Research Group | Completed | Met primary |
| Phase 2 | NCT01776008 | Jan 2013 → May 2015 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01368263 | Sep 2011 → May 2013 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01377389 | Jun 2011 → Apr 2017 | prostate cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01023061 | Mar 2010 → Sep 2015 | prostate adenocarcinoma | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00970203 | Sep 2009 → Oct 2018 | prostate cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00937768 | Jul 2009 → Jun 2012 | prostate adenocarcinoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT00771017 | Jul 2008 → ? | prostate cancer | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT00658697 | Jun 2008 → Sep 2014 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00528866 | Apr 2008 → Dec 2013 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00589472 | Nov 2007 → Jun 2010 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00432172 | Apr 2007 → Sep 2010 | breast cancer | Spanish Breast Cancer Research Group | Completed | Missed primary |
| Phase 2 | NCT00498901 | Feb → Dec 2007 | breast cancer | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT00544830 | Jul 2006 → Mar 2011 overdue | prostate adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00382057 | May 2006 → Mar 2011 | metabolic syndrome X | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00348998 | Apr 2006 → ? | prostate cancer | Virginia Mason Hospital/Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00322348 | Apr 2006 → Nov 2009 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00349557 | Apr 2006 → ? | prostate cancer | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00303524 | Feb 2006 → Aug 2007 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00532272 | Oct 2005 → Apr 2008 | breast cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00217659 | Sep 2005 → Jan 2007 | breast cancer | SWOG Cancer Research Network | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01076335 | May 2005 → Jun 2015 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00196846 | Mar 2005 → Dec 2008 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00103376 | Oct 2004 → Oct 2009 | prostate cancer | Medical University of South Carolina | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00165399 | Mar 2004 → Dec 2005 | prostate adenocarcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01014507 | Jan 2004 → Sep 2009 | Hodgkins lymphoma | University of Cologne | Completed | Missed primary |
| Phase 2 | NCT00235937 | Dec 2001 → Dec 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00028769 | Dec 2001 → Jun 2010 | prostate cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00586898 | Jul 2001 → Mar 2009 | cancer, prostate disorder | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00016913 | May 2001 → Jul 2007 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01250717 | Jan 2001 → May 2011 | prostate cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00186121 | Oct 2000 → May 2013 | breast cancer | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00006359 | Sep 2000 → Oct 2007 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00012090 | Sep 2000 → Apr 2004 | fallopian tube carcinoma, ovarian carcinoma, peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00010010 | Jun 2000 → May 2001 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06009627 | Apr 2023 → Mar 2025 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05253066 | Feb → Jul 2022 | breast neoplasm | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03373708 | Dec 2017 → Dec 2019 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT02221999 | Sep 2013 → Jan 2019 overdue | breast mucinous carcinoma, inflammatory breast carcinoma, invasive tubular breast carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01603420 | Jul 2012 → May 2014 | prostate cancer | Proton Collaborative Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 347 trials · 9 met primary · 5 missed | ||||||
| Phase 3 | NCT03936933 | Oct 2020 → Sep 2024 | breast cancer | Eurofarma Laboratorios S.A. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03936218 | Sep 2020 → Nov 2023 | prostate cancer | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03658213 | Mar 2020 → Nov 2021 | breast cancer | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT03054168 | Dec 2016 → Nov 2018 | muscular atrophy | University of Nottingham | Unknown | No outcome recorded |
| Phase 3 | NCT02532400 | Mar 2016 → Mar 2019 | breast cancer | Ruijin Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02518191 | Sep 2015 → Jan 2021 | female breast carcinoma | Xiangyun Zong | Completed | Met primary |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02535221 | Jul 2015 → Jun 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| Phase 3 | NCT02483767 | Jun 2015 → Nov 2016 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02132390 | May 2014 → May 2024 | breast cancer, chemotherapy-induced toxicity | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02003209 | Feb 2014 → Oct 2016 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01638247 | Aug 2012 → May 2018 | male breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01622361 | Jun 2012 → Feb 2016 | breast cancer | Asan Medical Center | Unknown | Missed primary |
| Phase 3 | NCT01492972 | Jan 2012 → Dec 2027 expected | prostate cancer | Proton Collaborative Group | Recruiting | No outcome recorded |
| Phase 3 | NCT01368588 | Jul 2011 → Apr 2025 overdue | prostate cancer | Radiation Therapy Oncology Group | Active not recruiting | Missed primary |
| Phase 3 | NCT01530607 | Nov 2009 → Nov 2012 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 3 | NCT00936390 | Sep 2009 → Oct 2020 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT01712893 | Jun 2009 → Aug 2017 | breast cancer | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT00912548 | May 2009 → Dec 2015 | breast cancer | Korean Breast Cancer Study Group | Unknown | Met primary |
| Phase 3 | NCT00948805 | Jan → Dec 2009 | infertility disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT01352091 | May 2008 → May 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00567580 | Feb 2008 → Jul 2018 | prostate cancer | Radiation Therapy Oncology Group | Unknown | Met primary |
| Phase 3 | NCT01581944 | Jan 2008 → Dec 2011 | leiomyoma | Mt. Hope Maternity Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00541047 | Nov 2007 → Jul 2022 | prostate cancer, sexual disorder | University College, London | Completed | Mixed |
| Phase 3 | NCT00430183 | May 2007 → Oct 2018 overdue | prostate cancer | Alliance for Clinical Trials in Oncology | Active not recruiting | Missed primary |
| Phase 3 | NCT00439751 | Apr 2007 → Dec 2015 | prostate cancer | Ontario Clinical Oncology Group (OCOG) | Completed | No outcome recorded |
| Phase 3 | NCT00423475 | Oct 2006 → Mar 2015 | prostate cancer | UNICANCER | Completed | Met primary |
| Phase 3 | NCT00429403 | Aug 2006 → Jul 2010 | breast cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00427245 | Aug 2004 → ? | breast cancer, infertility disorder, premature menopause | Anglo Celtic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00068601 | Oct 2003 → Jan 2014 | breast cancer, infertility disorder, premature menopause | SWOG Cancer Research Network | Completed | Met primary |
| Phase 3 | NCT00067015 | May 2003 → Oct 2004 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00021450 | Apr 2001 → Apr 2008 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 3 | NCT00014586 | Jan 2001 → Feb 2003 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00223145 | Dec 2000 → Dec 2026 expected | prostate cancer | Abdenour Nabid | Active not recruiting | Met primary |
| Phase 3 | NCT00223171 | Oct 2000 → Dec 2026 expected | prostate cancer | University of Sherbrooke | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00005044 | Feb 2000 → Sep 2012 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00002881 | Oct 1996 → Apr 1998 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002651 | May 1995 → Jun 2013 | prostate cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00769548 | Apr 1995 → Apr 2001 | prostate cancer | Radiation Therapy Oncology Group | Completed | Mixed |
| Phase 3 | NCT00002597 | Oct 1994 → Jul 2011 | prostate cancer | Radiation Therapy Oncology Group | Completed | Met primary |
| Phase 3 | NCT00002582 | Jun 1993 → Apr 2007 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 3 | NCT00002580 | Jun 1993 → ? | breast cancer | Scottish Cancer Therapy Network | Completed | No outcome recorded |
| Phase 3 | NCT00309478 | Dec 1990 → Jun 2004 | female breast carcinoma | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00002460 | Sep 1987 → ? | female breast carcinoma | Cancer Research UK | Unknown | No outcome recorded |
| Phase 3 | NCT00849082 | May 1987 → Nov 1995 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 3 | NCT00888082 | ? → Apr 2012 | breast cancer, ovarian dysfunction | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT00767286 | ? → Nov 2003 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT06523530 | Nov 2024 → Apr 2027 expected | NAFLD1, endometriosis | Aristotle University Of Thessaloniki | Recruiting | No outcome recorded |
| Phase 4 | NCT06455969 | Jul 2024 → Aug 2026 overdue | hypogonadism, musculoskeletal system disorder | Bradley Nindl | Recruiting | No outcome recorded |
| Phase 4 | NCT05333328 | Feb 2023 → Jan 2031 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Gangnam Severance Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03971110 | Jan 2021 → Nov 2022 | prostate cancer | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04248621 | Jan 2020 → Apr 2022 | prostate neoplasm | Wonju Severance Christian Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01738724 | Jan 2012 → Dec 2016 | leiomyoma | University of Sao Paulo | Terminated | No outcome recorded |
| Phase 4 | NCT00851461 | Apr 2008 → Nov 2011 | Kennedy disease, bulbospinal muscular atrophy | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00654524 | Mar 2008 → Dec 2009 | endometriosis | Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT00286351 | Jan 2005 → ? | endometriosis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00293696 | Oct 2004 → Nov 2006 | prostate cancer | Tampere University | Completed | No outcome recorded |
| Phase 4 | NCT00255268 | Aug 2004 → ? | metastatic prostate carcinoma | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 4 | NCT00293670 | May 1997 → Apr 2015 | — | Tampere University | Unknown | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07552480 | May 2026 → May 2027 expected | disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid system neoplasm, ovarian dysfunction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07552493 | May 2026 → May 2027 expected | disease related to hematopoietic stem cell transplant, ovarian dysfunction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07552506 | May 2026 → May 2027 expected | aplastic anemia, disease related to hematopoietic stem cell transplant, ovarian dysfunction | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07172685 | Jul 2025 → Jun 2026 overdue | prostate cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT06636591 | Dec 2024 → Jan 2026 | Her2-receptor negative breast cancer, female breast carcinoma | Fudan University | Completed | No outcome recorded |
| — | NCT05898321 | Jun 2023 → Dec 2024 | submucous uterine fibroid | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| — | NCT04220398 | Jan 2020 → Dec 2022 | chemotherapy-induced toxicity, prostate carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03440879 | Sep 2018 → Mar 2023 | prostate cancer | Norwegian School of Sport Sciences | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02932761 | Nov 2016 → Jan 2018 | — | Xipeng Wang | Unknown | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02779387 | May 2016 → May 2020 | infertility disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT00827307 | Jun 2008 → Jun 2011 | hyperlipidemia | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| — | NCT00488722 | Apr 2007 → Mar 2009 | breast cancer | Tianjin Medical University | Unknown | No outcome recorded |
| — | NCT00114114 | Sep 2004 → Nov 2017 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00031850 | Mar 2000 → May 2007 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Comparator or background therapy191 trials | ||||||
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07389187 Background | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05870579 Background | Nov 2023 → Dec 2026 expected | breast cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05856630 Comparator | May → Dec 2023 | prostate cancer | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05755581 Comparator | Apr 2023 → Apr 2025 | breast cancer | Sohag University | Unknown | No outcome recorded |
| Show all 191 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Atossa Therapeutics, Inc. | Results Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium atossatherapeutics.com ↗
(Z)-endoxifen with Ovarian Function Suppression (OFS) may offer a more tolerable and biologically potent alternative to aromatase-inhibitor (AI)-based regimens for premenopausal ER+/HER2– patients, potentially expanding endocrine therapy options and improving adherence while maintaining robust neoadjuvant efficacy |
| 2024-12-12 | TerSera Therapeutics LLC | Results TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer Symposium tersera.com ↗
Our data suggests that the 10.8 mg dose given every 12 weeks may also be an effective option. |
| 2024-12-10 | Atossa Therapeutics, Inc. | Results Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium atossatherapeutics.com ↗
Primary Endpoint Achieved: 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500–1000 ng/mL. |
| 2024-05-07 | TerSera Therapeutics LLC | Regulatory Health Canada approves ZOLADEX® LA for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women. tersera.com ↗ |
| 2020-05-27 | Novartis Pharmaceuticals | Results Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease novartis.com ↗
Results add to body of evidence, reinforce Kisqali consistent overall survival benefit regardless of type of metastases, endocrine partner or menopausal status |
| 2017-12-06 | Novartis Pharmaceuticals | Results Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer novartis.com ↗
Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early response with separation of the PFS curves as early as eight weeks[1] |
| 2017-11-08 | Novartis Pharmaceuticals | Results Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer novartis.com ↗
MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal women with HR+/HER2- advanced breast cancer |
All press releases naming this drug 14 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 349 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Goserelin | “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗244“METHODS: Forty women were assessed for eligibility at gynaecology clinics in the region, of whom thirty premenopausal women scheduled for hysterectomy due to symptomatic...” PMID 24608161 ↗ Mar 2014 “Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single...” NCT03054168 ↗ “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗ “Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the...” NCT04557059 ↗ “Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve...” NCT02867020 ↗ “In patients randomized to receive GnRHa, 3.6 mg of goserelin or 3.75 mg of leuprorelin was injected subcutaneously once every 28 days from 1 to 2 weeks before the first cycle...” PMID 34967844 ↗ Feb 2022 “A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With...” NCT03971110 ↗ “LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3...” NCT01088529 ↗ “Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days...” NCT03969121 ↗ “Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or...” NCT02440230 ↗ |
| Known as | goserelin acetate | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗80“Patients receive multitargeted tyrosine kinase inhibitor PLX3397 orally (PO) twice daily (BID) for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday)...” NCT02472275 ↗ “Primary Objective: * To determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing neoadjuvant and/or adjuvant...” NCT00429403 ↗ “All subjects will receive androgen deprivation therapy with a LHRH agonist (any LHRH agonist such as leuprolide acetate or goserelin acetate is acceptable) or a LHRH antagonist...” NCT02582749 ↗ “A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and...” NCT00099086 ↗ “The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according...” NCT03332797 ↗ “Goserelin acetate implant (ZOLADEX), at a dose of 10.8 mg, will be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line.” NCT07450599 ↗ “Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation conditioning.” NCT07552506 ↗ “either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.” NCT00016913 ↗ “luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.” NCT02217566 ↗ “3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation.” NCT00948805 ↗ |
| Known as | goserelin acetate (Zoladex) | “goserelin acetate (Zoladex®)” NCT01531205 ↗ |
| Known as | Goserelin Depot | “Drug: Goserelin Depot” NCT07552506 ↗ |
| Known as | NSC-606864 | “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗ |
| Known as | ZDX | “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗1“luteinizing hormone-releasing hormone (LHRH) analog (buserelin [BSRL], goserelin [ZDX], or leuprolide [LEUP])” NCT00003653 ↗ |
| Known as | Zoladex | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗50“Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single...” NCT03054168 ↗ “Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout...” NCT06922318 ↗ “Patients in the combined-treatment group received 3.6 mg of goserelin (Zoladex) subcutaneously every four weeks starting on the first day of irradiation and continuing for three years” PMID 9233866 ↗ Jul 1997 “Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally” NCT01790126 ↗ “Flutamide, FLUT, NSC-147834; Goserelin, Zoladex, ZDX, NSC-606864; with irradiation of the whole pelvis followed by a boost to the prostate using photons of at least 6 MV.” NCT00769548 ↗ “CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection” NCT02932761 ↗ “Goserelin acetate implant (ZOLADEX), at a dose of 10.8 mg, will be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line.” NCT07450599 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix)” NCT06059118 ↗ “monthly injections of a luteinizing hormone-releasing hormone (LHRH) analog such as Lupron or Zoladex” NCT00283803 ↗ “group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)” NCT01218581 ↗ |
| Known as | ZOLADEXTM | “patients added Goserelin(ZOLADEXTM) to Tamoxifen” NCT00912548 ↗ |
| Action | Inhibit | “Leuprolide and goserelin-both approved to treat prostate cancer-reduce testosterone production” NCT00004635 ↗ |
| Modality | Other / unclassified | “Zoladex, a kind of luitinizing hormone releasing hormone analogue, can offer efficient estrogen suppression as well.” NCT00488722 ↗ |
| Route | Subcutaneous | “goserelin subcutaneously (SC)” NCT00002580 ↗ |